UCB's bimekizumab finally back on the FDA's review list after May rejection
28th December 2022 Uncategorised 0 UCB’s bimekizumab finally back on the FDA’s review list after May rejection
zbecker
Wed, 12/28/2022 – 11:17
More: UCB's bimekizumab finally back on the FDA's review list after May rejection
Source: fierce
